2021 Fiscal Year Final Research Report
The treatment strategy using a new Galectin-3 inhibitor for hepatocellular carcinoma and pancreatic cancer
Project/Area Number |
18K16342
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 55020:Digestive surgery-related
|
Research Institution | University of Toyama (2021) Gunma University (2018-2020) |
Principal Investigator |
|
Project Period (FY) |
2018-04-01 – 2022-03-31
|
Keywords | Galectin-3阻害薬 / 肝細胞癌 / 膵癌 |
Outline of Final Research Achievements |
A novel Galectin-3 inhibitor significantly suppressed the proliferative and invasive potential of hepatocellular carcinoma and pancreatic cancer cell lines in a volume-dependent manner without toxicity to normal hepatocytes. In vivo studies, intraperitoneal daily administration of Galectin-3 inhibitor suppressed the growth of subcutaneous tumors in mice with pancreatic cancer and was well tolerated. CAGE analysis showed that Galectin-3 inhibitors act in the nucleus and inhibit elements involved in DNA replication and the cell cycle. In addition, a patient-derived xenograft model of tumor tissue transplantation was successfully established in patients with intraductal papillary mucinous carcinoma and metastatic liver carcinoma.
|
Free Research Field |
肝胆膵外科
|
Academic Significance and Societal Importance of the Research Achievements |
本研究成果により肝胆膵癌のみならず、他の消化器癌に対しても新規Gal-3阻害薬を用いた治療戦略の可能性に迫ることができる。また、動物実験で有効な結果が得られれば、ヒトへの応用(臨床試験や創薬)に繋がる可能性がある。加えて、他の消化器癌バイオマーカーとの関連を探索・検証することにより、消化器癌における外科学、分子細胞生物学および薬理学を繋ぐ新たな概念が生まれる。
|